Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 31;29(14):1795–1807. doi: 10.1177/13524585231205708

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — EVOLVE-MS-1 study design.

BID: twice daily; DMF: dimethyl fumarate; DMT: disease-modifying therapy; DRF: diroximel fumarate; GI: gastrointestinal; RRMS: relapsing–remitting multiple sclerosis; W: week.

EVOLVE-MS-1 was conducted from 10 December 2015 to 11 November 2021.

^aAdapted from Naismith RT, et al. CNS Drugs. 2020;34(2):185–196; http://creativecommons.org/licenses/by-nc/4.0/.

^bAdapted from Naismith RT, et al. Mult Scler. 2020;26(13):1729–1739; http://creativecommons.org/licenses/by-nc/4.0/.

^cExclusion criteria for newly enrolled patients included the use of teriflunomide within 2 years of Visit 2 (Week 1); natalizumab within 2 months of Visit 2; alemtuzumab; fingolimod within 90 days of Visit 2; daclizumab within 6 months of Visit 2; or B-cell therapies within 12 months of screening.